Gabapentin Enacarbil

加巴喷丁酯

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameGabapentin Enacarbil
Drug Alias NameGabapentina enacarbilo加巴喷丁恩那卡比Gabapentine enacarbil加巴喷汀酯Gabapentinum enacarbilum +[15] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated calcium channel alpha2/delta subunit 2 blockersVoltage-gated calcium channel alpha2/delta subunit 1 blockers
TargetsVoltage-gated calcium channel alpha2/delta subunit 1Voltage-gated calcium channel alpha2/delta subunit 2
Therapy Area/IndicationsAlcoholismRestless Legs SyndromeNeuralgia, Postherpetic +[5] 
Global Approved IndicationsRestless Legs Syndrome
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2011/04/06
Country/TerritoryCanadaUnited StatesGermany +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesXenoport Inc
China Registration ClassN/A

Develop Information

Active CompaniesXenoport IncAstellas Pharma IncAzurity Pharmaceuticals Inc
Inactive CompaniesNational Institute On Alcohol Abuse And Alcoholism
Active IndicationsRestless Legs SyndromeNeuralgia, Postherpetic
Inactive IndicationsAlcoholismDiabetic NeuropathiesMigraine Disorders

Other Information

ATC CodeN02BF01
Related LinksWikipediaDrugBankKEGG